Significantly, 21 days following experimental MI in mice, a single intramyocardial injection of PLGA-IGF-1 NPs was enough to prevent cardiomyocyte death (p < 0.001), decrease infarct size (p < 0.05), and enhance left ventricle ejection fraction (p < 0.01) [109,110]. The gene discussed is IGF1; the disease is myocardial infarction.